Palsonify (paltusotine) is the first once-daily oral treatment for acromegaly, FDA approved in September 2025 for adults who didn’t get a good enough result from surgery or can’t have surgery. In plain terms: it’s a pill that can do the job the monthly injections have done for years, without the needle and without the end-of-month wear-off a lot of patients dread.
Dr. Van Dyke here, board certified endocrinologist. Acromegaly is a niche diagnosis, so if this is new to you, stay with me. If you or someone you love has it, this is one of the more meaningful approvals of the year, and I want to explain what it actually is and where it fits.
Key Takeaways
- Palsonify (paltusotine), from Crinetics, is the first and only once-daily oral therapy for acromegaly, FDA approved on September 25, 2025.
- It’s for adults who had an inadequate response to surgery, or for whom surgery isn’t an option.
- It’s a selective somatostatin receptor type 2 (SST2) agonist, the same target as the injectable drugs, delivered as a pill.
- In the PATHFNDR-1 and PATHFNDR-2 trials, it held IGF-1 steady in patients switched off monthly injections and lowered IGF-1 in untreated patients, with symptom relief.
- You take it once daily with water on an empty stomach. Watch for gallstones, blood-sugar changes, a slow heart rate, and thyroid effects.
What is acromegaly, in plain terms?
Acromegaly is what happens when your body makes too much growth hormone, almost always because of a benign tumor on the pituitary gland at the base of your brain. Too much growth hormone drives up a second hormone called IGF-1, and that’s the one that does the damage over time: enlarged hands and feet, changes in facial features, joint pain, headaches, sweating, sleep apnea, and, if it’s left unchecked, effects on the heart and metabolism.
The number we watch to manage it is IGF-1. Getting IGF-1 back into a normal range is the whole goal of medical treatment, because that’s what protects the body long term.
What is Palsonify (paltusotine)?
Palsonify is the brand name. Paltusotine is the molecule, made by Crinetics. It’s a selective somatostatin receptor type 2 (SST2) agonist, which is the same target the standard injectable acromegaly medications hit. The difference is the format. This is the first version of that mechanism you can take as a once-daily pill instead of a shot.
The FDA approved it on September 25, 2025, for adults with acromegaly who had an inadequate response to surgery, or for whom surgery isn’t an option. Surgery to remove the pituitary tumor is still often the first step. Palsonify is for the large group of patients who need ongoing medical control after that, or who can’t have the operation.
How is an oral acromegaly pill different from the monthly injection?
This is the part that actually changes daily life, so let’s be specific.
For years, the mainstay has been a monthly depot injection of a peptide somatostatin receptor ligand. It works, but it has two real downsides. First, dialing in the correct dose can take many months of monthly visits. Second, a lot of patients feel their symptoms creep back toward the end of each monthly cycle, before the next injection. You get a good stretch, then a wear-off, then the next shot.
Palsonify moves that to a once-daily oral routine. You take it every day, so the level in your system is steadier day to day rather than peaking after an injection and fading before the next one. One practical detail: you take it with water on an empty stomach, so it fits into a morning routine the way a thyroid pill does.
How well does Palsonify work?
The approval rests on two phase 3 trials, and they tested two different real-world situations.
PATHFNDR-1 was the switch study. It took patients who were already controlled on monthly injectable medication and moved them to once-daily oral Palsonify. The point was to see whether the pill could hold the line. It did: it maintained IGF-1 control and symptom control after the switch.
PATHFNDR-2 was the harder test. It enrolled patients whose acromegaly was not medically controlled, with elevated IGF-1, and started them on Palsonify. Here the pill rapidly brought IGF-1 down and reduced symptom burden.
Long-term extension data presented at ENDO 2026 backed this up: after two years of treatment, Palsonify stayed effective and well tolerated in both groups, the patients switched off injections and the ones who were treatment-naive at the beginning. Patients also reported meaningful drops in the symptoms that make this disease hard to live with, including headaches, joint pain, sweating, fatigue, weakness, and swelling.
Who is Palsonify for, and who is it not for?
Palsonify is approved for adults with acromegaly who had an inadequate response to surgery, or for whom surgery isn’t an option. If you’ve had pituitary surgery and still need medical control, or you’re not a surgical candidate, this is squarely aimed at you.
It’s not a cure for the underlying pituitary tumor, and it’s not a decision to make casually. Whether you switch from a working monthly injection to a daily pill is a real clinical conversation about your numbers, your symptom pattern, and how you’d rather manage a lifelong condition. Some patients love being off injections. Others do fine on the monthly shot and prefer not to think about a daily pill. Both are reasonable.
What are the side effects and cautions?
No honest article skips this part. Palsonify is generally well tolerated, but it has a real safety profile you and your endocrinologist watch for.
The more common side effects, seen in more than 5% of patients, include diarrhea, abdominal pain, nausea, decreased appetite, a slow heart rate (sinus bradycardia), higher blood sugar, palpitations, and gastroenteritis. There are also specific things we monitor over time: gallstones and related gallbladder problems, blood-sugar changes in either direction, cardiac conduction effects, thyroid suppression, fatty stools, and vitamin B12 levels. And it interacts with certain medications, including some acid-reflux drugs and other prescriptions, so your full medication list matters.
None of that is a reason to be afraid of it. It’s the reason acromegaly is managed by an endocrinologist and not by autopilot.
How we manage acromegaly patients
Acromegaly isn’t a set-it-and-forget-it diagnosis, and a new oral option doesn’t change that. The work is in the follow-up: tracking your IGF-1 to confirm the medication is holding control, watching the safety labs, keeping an eye on the pituitary tumor with imaging over time, and adjusting when your numbers or symptoms drift. That kind of steady, between-visit attention is exactly what direct care is built for. A better drug plus close monitoring is what actually protects you.
The takeaway
Palsonify, paltusotine, is a real milestone: the first once-daily oral treatment for acromegaly, approved for adults who need medical control after surgery or who can’t have surgery. In the trials it held IGF-1 steady in patients switched off monthly injections and brought it down in untreated patients, with genuine symptom relief. It’s not a cure, it has a safety profile worth respecting, and whether it’s right for you is a conversation about your numbers and how you want to live with this condition. For a lot of patients, trading a monthly injection for a daily pill is a meaningful change.
Frequently asked questions
What is Palsonify (paltusotine) used for?
Palsonify is the first once-daily oral treatment for acromegaly in adults who had an inadequate response to surgery, or for whom surgery isn’t an option. It was FDA approved on September 25, 2025.
How is Palsonify different from acromegaly injections?
It targets the same somatostatin receptor (SST2) as the standard injectable drugs, but it’s a once-daily pill instead of a monthly shot. That means steadier day-to-day control and no needle, avoiding the end-of-month symptom wear-off some patients feel on monthly injections.
Does Palsonify work as well as the monthly injection?
In the PATHFNDR-1 trial, patients switched from monthly injections kept their IGF-1 and symptoms controlled on Palsonify. In PATHFNDR-2, untreated patients saw IGF-1 drop rapidly. Two-year data presented at ENDO 2026 showed durable control.
How do you take Palsonify?
It’s taken once daily by mouth, with water on an empty stomach.
What are the main side effects of Palsonify?
Common ones include diarrhea, abdominal pain, nausea, decreased appetite, a slow heart rate, higher blood sugar, and palpitations. Your endocrinologist also monitors for gallstones, thyroid suppression, and vitamin B12 levels, and reviews drug interactions.
Is Palsonify a cure for acromegaly?
No. It controls the disease by lowering IGF-1, but it doesn’t remove the underlying pituitary tumor. It’s ongoing medical management, which is why regular monitoring matters.
Have acromegaly and tired of monthly injections? Book a visit at the Advanced Institute for Diabetes & Endocrinology. We see patients in Mansfield, Texas in the office and remotely across seven states.
Drop your pituitary and acromegaly questions in the YouTube comments. We read every one, and they help us decide what to cover next.
Sources: Crinetics: FDA approval of Palsonify (paltusotine) · AJMC: Paltusotine FDA Approved for Acromegaly in Adults · Drugs.com: Palsonify FDA approval history · Crinetics: ENDO 2026 long-term PALSONIFY data